SCHEMBL4407573

SCHEMBL4407573

C[Si](C)(C)CCOc1ccc([N+](=O)[O-])cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.63
▸ MAPT P10636 7/20 0.62
▸ HPGD P15428 4/20 0.62
▸ LMNA P02545 4/20 0.62
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ ALDH1A1 P00352 2/20 0.62
▸ NPC1 O15118 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ CYP1A2 P05177 1/20 0.62
▸ CYP3A4 P08684 1/20 0.62
▸ CYP2D6 P10635 1/20 0.62
▸ CYP2C9 P11712 1/20 0.62
▸ CYP2C19 P33261 1/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.62
▸ S1PR4 O95977 7/20 0.48
▸ PDE7A Q13946 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.47
▸ MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15508874 0.89 RAB9A (0.55) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL6815842 0.84 MAPT (0.71) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL3441911 0.82 MAPT (0.69) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL6816060 0.82 MAPT (0.73) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL3694455 0.81 RAB9A (0.58) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL7778640 0.81 RAB9A (0.64) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL3857759 0.81 MAPT (0.63) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL6816187 0.80 MAPT (0.79) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL15321188 0.80 MAPT (0.56) RAB9AMAPTHPGDLMNASMN1; SMN2
SCHEMBL12189817 0.80 MAPT (0.70) RAB9AMAPTHPGDLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1924572-B1 REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES SMITHKLINE BEECHAM CORP (US) 2009-12-30 — — EP disclosed
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes SMITHKLINE BEECHAM CORPORATION 2008-10-09 — — US disclosed
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes SMITHKLINE BEECHAM CORPORATION 2008-10-09 — — US disclosed
EP-1924572-A1 REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES SmithKline Beecham Corporation (US) 2008-05-28 — — EP disclosed
WO-2007030366-A1 REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249301-A1 Regioselective Process for Preparing Benzimidazole Thiophenes CYP3A4, CYP2C19, CYP2B6 RAB9A 1271/4885MAPT 2606/4885HPGD 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback